Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Next Previous
Trial Profile

Efficacy and Safety of Fast-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec With or Without Metformin in Adults With Type 2 Diabetes (Onset 9)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin degludec (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms onset9
  • Sponsors Novo Nordisk

    • Most Recent Events

    • 25 Sep 2020 Results of post-hoc analysis confirming previous analysis (effects of fast-acting insulin aspart vs insulin aspart on PPG increments) and exploring efficacy and safety of FA vs IAs presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
    • 16 Jun 2020 Results of post-hoc analysis if 26 weeks presented at the 80th Annual Scientific Sessions of the American Diabetes Association
    • 16 Jun 2020 Post-hoc analysis results presented at the 80th Annual Scientific Sessions of the American Diabetes Association
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top